Literature DB >> 15593312

Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease.

Monty A Silverdale1, S L Nicholson, A R Crossman, J M Brotchie.   

Abstract

Overactive AMPA receptor-mediated transmission may be involved in the pathogenesis of levodopa-induced dyskinesia. The mechanism of action of the anticonvulsant drug topiramate involves attenuation of AMPA receptor-mediated transmission. In this study, the potential antidyskinetic action of topiramate was examined in the MPTP-lesioned marmoset model of Parkinson's disease and levodopa-induced dyskinesia. Topiramate significantly reduced levodopa-induced dyskinesia, without affecting the antiparkinsonian action of levodopa. Topiramate represents an exciting potential novel therapeutic approach to levodopa-induced dyskinesia in patients with Parkinson's disease. Copyright 2004 Movement Disorder Society.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15593312     DOI： 10.1002/mds.20345

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


  15 in total

1.  Improvement of cervico-trunco-brachial segmental dystonia with topiramate.

Authors:  Spiridon Papapetropoulos; Carlos Singer
Journal:  J Neurol       Date:  2005-11-22       Impact factor: 4.849

2.  Restless legs syndrome induced by topiramate: two more cases.

Authors:  Pedro Emilio Bermejo
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

Review 3.  Nondopaminergic treatments for Parkinson's disease: current and future prospects.

Authors:  Maria Eliza Freitas; Susan H Fox
Journal:  Neurodegener Dis Manag       Date:  2016-05-27

Review 4.  Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?

Authors:  Albert Y Hung; Michael A Schwarzschild
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 5.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

Review 6.  Glutamate receptors as therapeutic targets for Parkinson's disease.

Authors:  Kari A Johnson; P Jeffrey Conn; Colleen M Niswender
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

Review 7.  Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.

Authors:  Dhanya Vijayakumar; Joseph Jankovic
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

8.  Glutamatergic mechanisms in L-DOPA-induced dyskinesia and therapeutic implications.

Authors:  Manuela Mellone; Fabrizio Gardoni
Journal:  J Neural Transm (Vienna)       Date:  2018-01-31       Impact factor: 3.575

Review 9.  Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.

Authors:  Susan Duty
Journal:  CNS Drugs       Date:  2012-12       Impact factor: 5.749

Review 10.  Advances in non-dopaminergic treatments for Parkinson's disease.

Authors:  Sandy Stayte; Bryce Vissel
Journal:  Front Neurosci       Date:  2014-05-22       Impact factor: 4.677
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.